Drug
Cetuximab
Data on this page refer exclusively to patients treated with
Cetuximab combined with SBRT, without concurrent use of
drugs from other classes.
Combination therapy data and pooled group-level evidence are available on the
Anti-EGFR mAb group page.
Drug Profile
| Therapeutic Class | Monoclonal Antibodies (mAbs) |
| Drug Class | EGFR-Targeting |
| Group | Anti-EGFR mAb |
| Mechanism of Action | Anti-EGFR antibody |
| Half-life | 70-100 h |
Treated site
